S&P 500   3,901.36
DOW   31,261.90
QQQ   288.68
S&P 500   3,901.36
DOW   31,261.90
QQQ   288.68
S&P 500   3,901.36
DOW   31,261.90
QQQ   288.68
S&P 500   3,901.36
DOW   31,261.90
QQQ   288.68
NASDAQ:TCDA

Tricida (TCDA) Stock Forecast, Price & News

$9.59
-0.36 (-3.62%)
(As of 05/20/2022 04:00 PM ET)
Add
Compare
Today's Range
$9.43
$10.22
50-Day Range
$7.31
$11.85
52-Week Range
$3.55
$12.45
Volume
312,000 shs
Average Volume
378,865 shs
Market Capitalization
$531.53 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
0.91
30 days | 90 days | 365 days | Advanced Chart
Receive TCDA News and Ratings via Email

Sign-up to receive the latest news and ratings for Tricida and its competitors with MarketBeat's FREE daily newsletter.

Tricida logo

About Tricida

Tricida, Inc. operates as a pharmaceutical company. It focuses on the development and commercialization of veverimer (TRC101), a non-absorbed orally-administered polymer that has completed Phase III trial to treat metabolic acidosis in patients with chronic kidney disease by binding and removing acid from the gastrointestinal track. The company was incorporated in 2013 and is headquartered in South San Francisco, California.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:TCDA
Fax
N/A
Employees
57
Year Founded
N/A

Sales & Book Value

Annual Sales
N/A
Book Value
($1.63) per share

Profitability

Net Income
$-176.57 million
Pretax Margin
N/A

Debt

Price-To-Earnings

Miscellaneous

Free Float
16,406,000
Market Cap
$531.53 million
Optionable
Not Optionable

Company Calendar

Last Earnings
3/29/2022
Today
5/22/2022
Next Earnings (Estimated)
8/08/2022
Fiscal Year End
12/31/2022

MarketRank

Overall MarketRank

2.34 out of 5 stars

Medical Sector

235th out of 1,416 stocks

Pharmaceutical Preparations Industry

86th out of 677 stocks

Analyst Opinion: 3.3Community Rank: 3.6Dividend Strength: 0.0Insider Behavior: 4.2Valuation: 0.6 5 -4 -3 -2 -1 -













Tricida (NASDAQ:TCDA) Frequently Asked Questions

Is Tricida a buy right now?

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Tricida in the last year. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Tricida stock.
View analyst ratings for Tricida
or view top-rated stocks.

When is Tricida's next earnings date?

Tricida is scheduled to release its next quarterly earnings announcement on Monday, August 8th 2022.
View our earnings forecast for Tricida
.

How were Tricida's earnings last quarter?

Tricida, Inc. (NASDAQ:TCDA) posted its earnings results on Tuesday, March, 29th. The company reported ($0.92) EPS for the quarter, missing analysts' consensus estimates of ($0.71) by $0.21. During the same period in the previous year, the company earned ($1.09) EPS.
View Tricida's earnings history
.

What price target have analysts set for TCDA?

3 analysts have issued 1 year price objectives for Tricida's stock. Their forecasts range from $7.00 to $25.00. On average, they expect Tricida's stock price to reach $16.67 in the next twelve months. This suggests a possible upside of 73.8% from the stock's current price.
View analysts' price targets for Tricida
or view top-rated stocks among Wall Street analysts.

Who are Tricida's key executives?
Tricida's management team includes the following people:
  • Dr. Gerrit Klaerner Ph.D., Founder, Pres, CEO & Exec. Director (Age 50, Pay $719.98k)
  • Mr. Geoffrey M. Parker, COO, CFO & Exec. VP (Age 57, Pay $502.33k)
  • Mr. Robert L. McKague J.D., Exec. VP, Company Sec., Gen. Counsel & Chief Compliance Officer
  • Dr. Dawn Parsell Ph.D., Exec. VP of Clinical Devel. (Age 60, Pay $504.92k)
  • Ms. Annie Yoshiyama, VP of Fin. & Chief Accounting Officer (Age 39)
  • Jackie Cossmon, VP of Investor Relations & Communications
  • Mr. Edward J. Hejlek Esq., J.D., Exec. VP of Intellectual Property (Age 65)
What is Gerrit Klaerner's approval rating as Tricida's CEO?

2 employees have rated Tricida CEO Gerrit Klaerner on Glassdoor.com. Gerrit Klaerner has an approval rating of 100% among Tricida's employees. This puts Gerrit Klaerner in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Tricida own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Tricida investors own include Pfizer (PFE), Sorrento Therapeutics (SRNE), Gilead Sciences (GILD), Dynavax Technologies (DVAX), VBI Vaccines (VBIV), Aldeyra Therapeutics (ALDX), Atara Biotherapeutics (ATRA), bluebird bio (BLUE), Moderna (MRNA) and AT&T (T).

When did Tricida IPO?

(TCDA) raised $175 million in an IPO on Thursday, June 28th 2018. The company issued 10,300,000 shares at $16.00-$18.00 per share. Goldman Sachs, J.P. Morgan and Cowen served as the underwriters for the IPO.

What is Tricida's stock symbol?

Tricida trades on the NASDAQ under the ticker symbol "TCDA."

Who are Tricida's major shareholders?

Tricida's stock is owned by many different institutional and retail investors. Top institutional shareholders include Deep Track Capital LP (4.79%), Frazier Life Sciences Management L.P. (3.76%), Vanguard Group Inc. (2.58%), Great Point Partners LLC (2.26%), Bleichroeder LP (2.16%) and BlackRock Inc. (1.74%). Company insiders that own Tricida stock include Brian M Isern, Geoffrey M Parker, Gerrit Klaerner, Kurtis R Kurimsky, Robert Mckague and Sandra I Coufal.
View institutional ownership trends for Tricida
.

Which institutional investors are selling Tricida stock?

TCDA stock was sold by a variety of institutional investors in the last quarter, including GSA Capital Partners LLP, Bleichroeder LP, Great Point Partners LLC, Connor Clark & Lunn Investment Management Ltd., Renaissance Technologies LLC, Russell Investments Group Ltd., and Stratos Wealth Partners LTD.. Company insiders that have sold Tricida company stock in the last year include Brian M Isern, Gerrit Klaerner, and Sandra I Coufal.
View insider buying and selling activity for Tricida
or view top insider-selling stocks.

Which institutional investors are buying Tricida stock?

TCDA stock was purchased by a variety of institutional investors in the last quarter, including Frazier Life Sciences Management L.P., Deep Track Capital LP, J. Goldman & Co LP, Simplex Trading LLC, Cresset Asset Management LLC, Victory Capital Management Inc., Jane Street Group LLC, and Wellington Management Group LLP. Company insiders that have bought Tricida stock in the last two years include Geoffrey M Parker, and Robert Mckague.
View insider buying and selling activity for Tricida
or or view top insider-buying stocks.

How do I buy shares of Tricida?

Shares of TCDA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Tricida's stock price today?

One share of TCDA stock can currently be purchased for approximately $9.59.

How much money does Tricida make?

Tricida has a market capitalization of $531.53 million. The company earns $-176.57 million in net income (profit) each year or ($2.890010) on an earnings per share basis.

How many employees does Tricida have?

Tricida employs 57 workers across the globe.

What is Tricida's official website?

The official website for Tricida is www.tricida.com.

How can I contact Tricida?

Tricida's mailing address is 7000 SHORELINE COURT SUITE 201, SOUTH SAN FRANCISCO CA, 94080. The company can be reached via phone at (415) 429-7800 or via email at [email protected].

This page was last updated on 5/23/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.